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Abstract
There is an urgent need for the application of new protein markers in early 
and personalized prognostic diagnosis of cancer. As with many other types 
of malignancies, the number of leukemia-affected patients is on the rise. This 
requires novel tools when it comes to efficient treatment approaches, specifically 
those that are preventative and highly precise. Numerous important discoveries 
have recently been published regarding new proteins and their pathology-related 
modifications, which may play important roles in the onset and progression of 
leukemia. Chronic and acute lymphocytic leukemia are represented by important 
changes in lymphocyte cell metabolism, where many of the regulating trans-
membrane protein markers demonstrate altered functions in the regulation of 
crucial cell transduction signaling pathways. The most notable progress thus far 
has been achieved in studies concerning CD5, CD10, CD19, CD20, CD22, CD23, 
and CD52 protein markers and their associated proteins. As such, some of these 
signals may be applied in specific and personalized diagnostics as well as drug 
development.
Keywords: chronic lymphocytic leukemia, acute lymphocytic leukemia, 
protein markers, disease proteomics, personalized cancer diagnosis
1. Introduction
Chronic lymphocytic leukemia (CLL) is the most common malignancy in adults, 
and acute lymphocytic leukemia (ALL) is the most common pediatric cancer 
in western countries. These leukemic diseases affect the lymphoid line of blood 
cells. In most cases, the cause is unknown, hypothesizing that multiple genetic 
mutations and epigenetic changes are involved. Both diseases are vastly heteroge-
neous. While CLL is generally considered incurable and progresses slowly in most 
cases, ALL progresses rapidly and is typically fatal within weeks or months if left 
untreated. Historically, survival rates have been poor for patients with ALL. Since 
the introduction of chemotherapy, prognosis for childhood leukemia has improved 
greatly, and children with ALL are estimated to have a 95% probability of achieving 
successful remission. However, a total of 10–15% of patients still relapse despite 
undergoing intensive chemotherapy, and outcomes are far less encouraging in 
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adults. CLL treatment tends to focus mainly on controlling the state of the disease 
and its associated symptoms, rather than on its definitive eradication. The specifics 
of treatment will largely depend on the patient’s prognosis and the specific CLL 
subtype. Therefore, lifelong observation and follow-up are strongly recommended 
and supported for all the patients. The combination of chemotherapy and non-
chemotherapeutic drugs has improved survival of CLL patients overall, leading to 
long-lasting remissions. The pathology of CLL is complex in that it is influenced 
by a number of genetic and molecular changes, the CLL microenvironment, as 
well as various signaling pathways, of which the B-cell receptor (BCR) signaling 
pathway is central to CLL activation. Signaling pathways that are identified as being 
affected in CLL patients can provide opportunities for the development of disease-
specific drugs to the extent that they may be applicable in future clinical testing 
and molecular treatments. In any type of cancer, molecular therapy which targets 
specific regulatory proteins or their disease-associated posttranslational modifica-
tions can make way for novel applications which provide even higher specificity and 
efficiency with regard to treatment. This approach certainly applies to any type of 
leukemia.
2. Chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia in the 
western world. The disease typically occurs in elderly patients and has a highly vari-
able clinical progression. CLL is characterized by the clonal expansion and accumu-
lation of mature CD19+, CD5+, and CD23+ B lymphocytes in the peripheral blood, 
bone marrow, and secondary lymphoid organs [1]. CLL cells are phenotypically 
similar to antigen-experienced B cells and show gene expression profiles similar 
to memory B cells [2]. The cellular origin of CLL is still debated, but it is assumed 
that CLL cells originate either from unmutated mature CD5+ B cells or CD5+CD27+ 
post-germinal center B-cell subsets [3]. CLL cells recirculate between peripheral 
blood and secondary lymphoid organs, where they proliferate in distinct areas of 
tissue, termed “pseudofollicles,” at a daily birth rate of approximately 1–2% of the 
entire clone size [4]. Survival of CLL cells strictly depends on a permissive microen-
vironment composed of cellular components such as monocyte-derived nurse-like 
cells, T cells, follicular dendritic cells, mesenchymal stromal cells, and endothelial 
cells. Such dynamic combination of components leads to the presence of molecules 
such as cytokines, chemokines, and angiogenic factors. Leukemic cells take advan-
tage of these vital proteins by interacting with them via cell-surface receptors or cell 
adhesion molecules to further facilitate their proliferation and survival [5, 6]. CLL 
cells are also characterized by an often observed defect in apoptosis which allows 
peripheral blood B lymphocytes to survive [7].
Autoantigens and/or autonomous mechanisms activate the BCR and its signaling 
cascade in secondary lymphatic tissues, playing a central pathogenic role in CLL 
[8]. These events result in activation of multiple downstream regulators in B cells 
which ultimately mediate changes in cell proliferation, survival, and migration via 
both transcriptional modulation and phosphorylation. BCR signaling responses 
in CLL cells are heterogeneous, with effective activation of only a selected set of 
downstream responses [9]. Another key property of BCRs is that they exhibit 
somatic mutations in varying amounts; importantly, the degree of mutation has 
been found to inform the prognosis of disease [2, 10]. Furthermore, many cases 
of CLL (approximately one third) are characterized by a nearly indistinguishable 
subset of BCRs exhibiting shared antigens. This suggests a close link between these 
specific molecules and CLL pathogenesis.
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CLL cells usually show constitutive phosphorylation of signaling proteins which 
promote their proliferation and survival, leading to pathological processes. Protein 
phosphorylation in lymphocytes is tightly associated with the regulation of a 
variety of protein activities, functional regulation, and cell signaling and may thus 
affect initiation and/or progression of the disease. As such, protein phosphorylation 
may be one of the most promising targets for the discovery of novel cancer-related 
protein markers and in turn their application in new approaches to molecular 
therapy. The constitutive activation of proteins by phosphorylation presents 
its potential for prognostic significance, as the identification of aberrant signal 
transduction in leukemic cells can become a potential target for novel agents. After 
BCR stimulation, CLL cells have shown a tendency toward impaired phosphoryla-
tion levels. Higher basal phosphorylation levels of PLCγ2 (pY759), p44/42 MAPK 
(pT202/Y204), p38 MAPK (pT180/Y182), NF-κB p65 (pS529), STAT5 (pY694), and 
STAT6 (pY641) were detected in CLL cells compared to normal B cells, predicting 
their impaired function [12]. As such, these markers may represent some of the 
novel protein targets involved in the development of efficient therapeutics. Cancer 
cells with constitutive STAT3 activation have been reported to have elevated levels 
of cell cycle regulation and antiapoptotic proteins, leading to apoptotic resistance. 
Constitutive serine phosphorylation of STAT1 and STAT3 has also been reported 
in CLL cells [13]. More recently, new phosphorylations on threonine (pThr314) 
and two serine residues (pSer254, pSer265) of CD23, which is overexpressed and 
abnormally regulated in CLL, were reported in B lymphocytes of B-CLL patients 
[14]. Regulation of these CD23, CLL-associated phosphorylation sites brings new 
insight to the involvement of this transmembrane protein marker in the onset and 
progress of CLL.
2.1 Incidence and risk
CLL is the most common leukemia in western countries, with an estimated 
incidence of about 4.5 new cases per 100,000 individuals annually [1]. It is most 
frequent in white populations in the United States and the lowest in Eastern Asian 
populations [15]. Median age at diagnosis is usually 72 years, and more male than 
female patients (1.7:1) are affected. About 10% of CLL patients are reported to be 
younger than 55 years of age [16].
The etiology of CLL is still unknown. Genetics and environmental factors 
may play an important role. Over 25 gene polymorphisms have been identified as 
contributing to CLL from a familial standpoint. These include genes that play roles 
in apoptosis, B-cell biology, as well as regulation by microRNAs, all of which have 
been found to be involved in disease progression [17, 18]. As such, it is important 
to note that relative to the general population, a six- to ninefold greater risk of 
developing the disease exists in individuals who have or have had relatives with 
CLL. Consequent protein synthesis and the involvement of newly synthesized 
proteins in disease onset and progression are the focus of numerous current studies. 
Insecticide exposure and farming history have also been associated with a higher 
environmental risk for developing CLL [19].
2.2 Symptoms and diagnosis
According to the International Workshop on Chronic Lymphocytic Leukemia 
(iwCLL) 2008 guidelines [20], a CLL diagnosis is established by the presence 
of more than 5 × 109/L peripheral lymphocytes, which lasts for a duration of 
at least 3 months, co-expressing CD5-, CD19-, and CD23-positive and weakly 
expressing CD20- and CD79b-positive as well as surface immunoglobulins. 
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Immunophenotyping by flow cytometry is required to establish CLL diagnosis 
based on cell identity, clonality, and quantity [21].
Two clinical staging systems, the Rai et al. [22] and Binet et al. [23] systems, 
are used to group patients with CLL into risk groups with discrete clinical out-
comes. These two staging systems are relatively simple and widely used, relying 
on a physical examination and standard laboratory tests. Notably, the clinical 
presentation of CLL at diagnosis is extremely variable. Approximately 60% of 
patients are asymptomatic, and it is possible to detect the presence of the disease 
via a routine blood cell count. Lymphadenopathy (80%) and splenomegaly 
(50%) may be observed. Hepatomegaly is less frequent. As the disease progresses, 
patients can have B symptoms (weight loss, fever, night sweats, weakness) and 
exhibit a higher risk of infections. Lymphocytosis is constantly present, but the 
absolute number of lymphocytes is extremely variable. Anemia and thrombo-
cytopenia may be also observed in 15–30% of patients [22–24]. Monoclonal B 
lymphocytosis (MBL), which can be observed in 5% of patients who exhibit a 
regular blood count and no other characteristics of a lymphoproliferative disposi-
tion, is characterized by a monoclonal B lymphocyte number of less than 5 × 109/L 
in circulating blood [25]. Advancement from MBL to CLL is seen in a frequency of 
1–2% cases per year [26].
Small lymphocytic lymphoma (SLL), in which the same leukemic cell popula-
tion is mostly restricted to the bone marrow and lymphoid tissues, is similarly 
managed but considered to be a single entity [27]. The transformation into Richter 
syndrome (most commonly diffuse large B-cell lymphoma) occurs in 5–10% of all 
CLL cases and usually has a very poor prognosis [16].
2.3 Prognostic factors
The most important prognostic factors aside from clinical Rai and Binet stag-
ing systems are serum markers including β2 microglobulin levels [28], thymidine 
kinase levels [29], soluble CD23 levels [30], cellular markers including CD38 [31] 
and ζ chain associated protein kinase 70 (ZAP70) [32], CD49d [33], chemokines 
CCL3 a CCL4, genetic parameters including the mutational status of IGHV 
genes [10], and cytogenetic aberrations [34]. Unfavorable prognostic factors also 
include the male gender, ≥65 years of age, poor performance status due to medi-
cal comorbidities, late-stage disease at diagnosis, an initial white blood cell count 
above 35 × 109/L, lymphocyte doubling time of less than 6 months, and a diffuse 
histological pattern in bone marrow infiltration [35]. Elevated levels of beta-2 
microglobulin, serum thymidine, and serum CD23 at diagnosis also result in a poor 
prognosis [36].
ZAP-70 is a cytoplasmic protein tyrosine kinase initially identified in T cells. 
ZAP-70 expression in CLL is associated with increased BCR signaling capacity 
and greater responsiveness to chemokines resulting in more pronounced CLL 
cell migration and activation. Patients with ZAP-70 expression in more than 
20% of CLL cells have a relatively shorter median time from diagnosis to initial 
treatment [37], and ZAP-70 appears to be a risk factor that is closely linked 
to aggressive CLL [32]. CD38 is a transmembrane protein that supports B-cell 
interaction and differentiation through the binding of CD31 [38], a cell adhesion 
molecule expressed by cells of the CLL microenvironment. Patients with high 
CD38 expression experience faster progression and shorter life expectancy [31]. 
The expression of the surface molecule CD49d, the α4 subunit of the integrin 
heterodimer α4β1, promotes microenvironment-mediated proliferation of CLL 
leukemic cells and has been identified in a subgroup of patients characterized by 
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progression of disease and short survival [33]. Both CCL3 and CCL4 are mem-
bers of a cluster of cytokines with function as chemoattractants for monocytes 
and lymphocytes. They promote the communication of survival and proliferation 
signals to malignant cells and are associated with worse clinical outcomes in CLL 
[39, 40].
Immunoglobulin heavy-chain variable region (IGHV) mutation status plays 
an important role in CLL prognosis. Based on the degree of somatic hypermuta-
tion IGHV segments, unmutated IGHV (98% or more sequence homology with 
the germline sequence) corresponds to CLL originating from B cells that have not 
undergone a somatic mutation. Such patients can be classified as “unmutated” 
(U-CLL). Mutated IGHV (less than 98% sequence homology) is referred to as 
“mutated” (M-CLL) cases [41]. The presence of unmutated IGHV predicts a more 
aggressive disease type and has traditionally been associated with significantly 
decreased survival rates compared with mutated IGHV, which is associated 
with slower disease progression and longer survival [10, 31]. The differences in 
clinical behavior between M-CLL and U-CLL are determined by differences in 
responsiveness to external signals (such as BCR responsiveness). U-CLL BCRs 
are polyreactive and mostly recognize autoantigens and other environmental 
antigens [42, 43]. In contrast, affinity-matured BCRs from M-CLL cases bind to 
a restricted set of more specific antigens that either occur infrequently or induce 
anergy. Consequently, the M-CLL clone remains stable overall or expands at a 
slower rate [44, 45].
More than 80% of patients with previously untreated CLL have cytogenetic 
abnormalities, most common of which is a deletion in chromosome del(13q) 
[del(13q14.1)] (55%), followed by del(11q) [del(11q22-23)] (10–25%), trisomy 12 
(10–20%), and del(17p) [del(17p13)] (5–10%) [34, 46]. Recommended analyses 
include interphase cytogenetic analysis with FISH for the detection of the del(17p), 
which affects p53 expression. A positive outcome is often seen in individuals who 
have deletions in 13q. This is likely a result of two missing miRNAs typically found 
in 13q, miR-15-1, and miR-16-1, which exhibit strong activity in healthy B cells; 
miR-15-1 and miR-16-1 are thought to play a role in the downregulation of B-cell 
lymphoma 2 (BCL2), which acts as an antiapoptotic molecule [34].
The association between trisomy 12 and prognosis is still not clear [47]. A 
deletion in 11q results in the ataxia telangiectasia mutated (ATM) gene, which 
has shown to be a predictor of poor clinical outcome [34]. Deletions of the short 
arm of chromosome 17 cause the loss of one tumor protein p53 (TP53) allele and 
are associated with inactivating mutations in the other allele in 80% of patients 
with CLL. This cytogenetic aberration is associated with the worst CLL prognosis. 
Patients have shown marked resistance against genotoxic chemotherapies which 
has forced clinicians to alter their first-line treatment [34, 48]. Further recurring 
gene alterations have been found in 5% of cases of CLL samples at time of diagno-
sis; via whole genome/exome sequencing, genes influencing NOTCH1 and myeloid 
differentiation primary response (MYD88) [49] have been identified alongside 
genes coding for splicing factor 3B subunit 1 (SF3B1) [50] and baculoviral IAP 
repeat containing 3 (BIRC3) [51]. Patients experiencing progressive/refractory 
CLL and Richter’s syndrome were observed to exhibit these mutations in greater 
frequency [50].
2.4 Therapy
CLL is an incurable disease with a highly heterogeneous clinical course. 
Previous studies have shown that early treatment with chemotherapeutic agents 
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was unable to demonstrate a benefit due to these therapeutic interventions in 
CLL patients [52]. The standard treatment for patients with early disease is 
a “watch-and-wait” strategy. Treatment should only be initiated in patients 
with progressive or symptomatic/active disease. In order to determine the 
best approach to treatment, crucial factors such as the stage of disease, physi-
cal status, and cytogenetic risk should be assessed on a per-patient basis [18]. 
Additionally, the “Go-Go,” “Slow-Go,” and “No-Go” comorbidity classifications 
present another important set of factors in determining the optimal avenue for 
treatment [53].
Monotherapy with alkylating agents (chlorambucil) and purine analogs 
(fludarabine, pentostatin, cladribine, bendamustine) has served as an initial, 
frontline therapy for CLL and was the therapeutic “gold standard” for several 
decades [52]. Compared to monotherapy, the combination of fludarabine with 
alkylating cyclophosphamide is more widely used, leading to an increased effect 
on malignant lymphocytes and greater remission inductions [54]. The onset of 
biological treatment using monoclonal antibodies has led to significant changes 
in the approach to treatment. As CD20 is expressed on most B-cell malignancies, 
the introduction of the anti-CD20 antibody rituximab improved the treatment 
of most CD20-positive non-Hodgkin lymphomas, including CLL. Rituximab is 
less active as a single agent; however, combinations of rituximab with chemo-
therapy have shown to be very efficacious therapies for CLL [55]. The combina-
tion of rituximab, fludarabine, and cyclophosphamide is considered to be the 
standard first-line therapy (FCR chemoimmunotherapy) [56]. Ofatumumab 
and obinutuzumab are another set of CD20 antibodies used for the treatment of 
patients with relapsed/refractory CLL [57, 58]. Alemtuzumab is a recombinant, 
fully humanized, monoclonal antibody against the CD52 antigen. Monotherapy 
with alemtuzumab is used in patients with advanced CLL or relapsed patients 
after second-line fludarabine therapy and with poor prognostic features [59]. 
Autologous stem-cell transplantation is not useful in CLL. Maintenance therapy in 
CLL patients with higher risk of relapse may have some benefit but is not gener-
ally recommended [18].
Lenalidomide is an immunomodulatory agent that induces only mild apoptosis 
of leukemic cells but also reduces CLL proliferation through a cereblon-/p21-depen-
dent mechanism. Lenalidomide has pleiotropic effects on the CLL microenviron-
ment: it increases CD4+ T-mediated antigen presentation, proliferation, and 
activity and enhances NK and CD4+ T-cell mediated antitumor immune responses 
[60]. It is active alone, in CLL relapsed/refractory patients, or as an initial treatment 
for elderly patients or in combination with rituximab [61].
The CXCR4/CXCL12 signaling axis represents another important therapeutic 
target in CLL. CXCR4 antagonists have been developed, including peptide CXCR4 
antagonists (BKT140), small molecule CXCR4 antagonists (AMD3100, plerixafor), 
and antibodies to CXCR4 (MDX-1338) [62]. Plerixafor inhibits CXCL12-mediated 
signaling activation on CLL cells and is used in combination with rituximab in 
relapsed CLL patients [63].
Proteins in the Bcl-2 family are key regulators of the apoptotic process with 
proapoptotic and prosurvival activities. Venetoclax is a so-called BH3-mimetic 
drug designed to block the function of the Bcl-2 protein and inhibits the growth of 
BCL-2-dependent tumors in vivo. Monotherapy with this drug is active and well 
tolerated in patients with relapsed or refractory del(17p) CLL, providing a new 
therapeutic option for this very poor prognosis population [64].
B-cell receptor signaling seems to play an important role in the survival of CLL 
cells. Inhibitors targeting BCR-associated kinases have changed the landscape of 
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treatment for CLL patients, inducing durable remissions in relapsed/refractory 
patients, including those carrying unfavorable genetic alterations (e.g., del17p, 
del11q) [65]. Randomized trials comparing new drugs and/or their combinations 
with standard chemoimmunotherapy regimens are ongoing and will allow to 
better define optimal treatment strategies [66]. New light shed onto the mecha-
nisms of BCR activation in CLL has enabled for the design and application of 
kinase inhibitors targeting BCR signaling kinases BTK, PI3K, and SYK. Bruton’s 
tyrosine kinase, BTK, is a non-receptor tyrosine kinase that plays a central role in 
downstream activation of cell survival pathways such as NF-κB and MAP kinases 
via Src family kinases. Ibrutinib is the first human BTK inhibitor. The drug binds 
irreversibly to a cysteine residue (Cys-481) in the BTK kinase domain [67] and 
inhibits BTK phosphorylation and its enzymatic activity [68]. Ibrutinib inhibits 
CLL cell survival and proliferation, as well as leukemia cell migration toward the 
tissue homing chemokines [69]. Previous tests have shown that ibrutinib yielded 
durable remissions in CLL/SLL patients with relapsed, refractory, or high-risk 
disease and in previously untreated older patients [70]. Acalabrutinib, a poten-
tially more selective, irreversible BTK inhibitor has been tested and is currently 
under early clinical development [71]. PI3Kδ is expressed by hematopoietic cells 
and plays a critical role in B-cell homeostasis and function. Idelalisib is a highly 
selective PI3Kδ inhibitor, which antagonizes CLL-survival signals coming from 
the microenvironment as well as BCR stimulation [72]. This drug inhibits CLL 
cell chemotaxis toward CXCL12 and CXCL13 and migration beneath stromal cells 
and also inhibits BCR- and chemokine-receptor-induced AKT and MAP kinase 
activation [73]. Idelalisib has been tested as single agent or in combination strate-
gies with clinical benefit in patients with relapsed/refractory CLL [74]. Additional 
PI3K inhibitors are currently under development, including duvelisib, a potent 
PI3K γδ inhibitor, which antagonizes BCR and microenvironment interactions 
in vitro [75]. Spleen tyrosine kinase (SYK), which belongs to the SYK/ZAP70 
family of non-receptor kinases, has been implicated in tissue homing and reten-
tion of activated B cells due to its role as a downstream activator of BCR signaling 
(chemokine and integrin receptors) [76]. Up to this point, only limited responses 
have been seen in patients experiencing CLL relapse after introduction of fosta-
matinib disodium (FosD) to the treatment regimen [77]. FosD is currently the 
only available inhibitor of SYK on the market, with additional similar drugs being 
developed [78].
3. Acute lymphocytic leukemia
Acute lymphocytic leukemia (ALL), also known as acute lymphoblastic leuke-
mia or acute lymphoid leukemia, is the most common malignancy in children and 
the least common type of leukemia in adults. It is an acute type of cancer invading 
blood and spreading throughout the body to other organs, such as the liver, spleen, 
lymph nodes, and central nervous system. Without treatment, it can be fatal within 
a few months. ALL is characterized by a malignant transformation and prolifera-
tion of lymphoid progenitor cells in the bone marrow, blood, and extramedullary 
sites, which replace normal blood cells [79]. The exact causes of ALL remain largely 
unknown, but it is thought to result from genetic alterations such as structural 
chromosome rearrangements, aneuploidy, and mutations in genes that encode 
for transcription factors regulating lymphoid development, tumor suppressors, 
proteins that regulate cell cycle progression, and epigenetic modifiers. Such defects 
result in abnormal growth [80].
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3.1 Classification
ALL is a hematologic malignancy with uncontrolled proliferation of lympho-
blasts of B- or T-cell origin. ALL cases are clinically classified as B-cell precursor 
(BCP), mature B-cell, or T-cell types. BCP-ALL arises in B lymphocytes in the early 
stages of development in the bone marrow and affects 75–80% of adult patients. 
Mature B-cell ALL arises in more mature developing lymphocytes. This type of ALL 
is less common and accounts for around 3–5% of all adult cases. In around 20–25% 
of cases, ALL arises in developing T cells. This type of ALL can be further classified 
as early, mid, or late, depending on the maturity of the affected cell. T-cell ALL is 
commonly presented with a high white blood cell count and involvement of the 
central nervous system at diagnosis [81] (Table 1).
3.2 Incidence and risk
The incidence of ALL is estimated at 1.7 per 100,000 population in the United 
States [82] and 1.28 per 1 000,000 individuals in Europe [83] each year. ALL is the 
most frequent cancer in children, accounting for 30% of all cancers and 80% of leu-
kemias, with peak incidence occurring at 2–5 years of age. The incidence decreases 
with age progression and rises back up with a second peak in patients above the 
age of 50 years, representing about 15% of leukemias [84]. ALL is more common 
in males than females. Survival rates were poor 50 years ago, when leukemia was 
considered to be an intractable disease. Currently, pediatric patients with ALL 
have dramatic cure rates with 80–90% achieving complete remission (CR) [85]. 
However, prognoses in the elderly remain miserable. Despite a high rate of response 
to induction chemotherapy, only 30–40% of adult patients with ALL will achieve 
long-term remission [86].
There are a few risk factors which can increase the possibility for ALL, such 
as exposure to high levels of radiation, industrial chemicals (such as benzene), 
pesticides [87], certain types of chemotherapy used to treat other cancers, certain 
types of viral infections (human T-cell lymphoma/leukemia virus-1 or Epstein-Barr 
virus) [88], inherited genetic syndromes (such as Down syndrome) [89], and being 
white and male.
3.3 Symptoms and diagnosis
Most clinical manifestations of ALL exhibit the accumulation of malignant, 
poorly differentiated lymphoid cells within the bone marrow, peripheral blood, 
and other tissues. Symptoms of ALL are generally nonspecific with a combina-
tion of constitutional symptoms and signs of bone marrow failure (anemia, 
thrombocytopenia, leukopenia). Common symptoms include “B symptoms” 
ALL classification Subtypes Ref
B-ALL B-cell precursor ALL (75–80%) [81]
Mature B-cell ALL (3–5%)
T-ALL Early T-cell precursor ALL (20%)
Mid or late subtypes of T-ALL (5%)
Table 1. 
Classification of ALL subtypes.
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(fever, weight loss, night sweats), easy bruising or bleeding, fatigue, dyspnea, 
and infections. Lymphadenopathy, splenomegaly, or hepatomegaly can be 
also present [90, 91]. CNS involvement at time of diagnosis occurs in 5–8% of 
patients and presents most commonly as cranial nerve deficits or meningismus 
[86]. Current standards for the diagnosis of ALL are based on the classification 
of lymphoid neoplasms according to the World Health Organization (WHO) 
2008 criterion [92]. Diagnosis of ALL is established by the presence of 20% or 
more lymphoblasts in the bone marrow or peripheral blood [90]. Flow cytometry 
and cytogenetic testing are needed to confirm the diagnosis and provide risk 
stratification. Immunophenotyping by flow cytometry has become the standard 
procedure for ALL diagnosis and subclassification and was also developed as 
a useful tool for the detection and monitoring of minimal residual disease. In 
B-lineage ALL, the most important markers for diagnosis, differential diagnosis, 
and subclassification are CD19, CD10, CD20, CD22, CD24, and CD79a [93, 
94]. For T-lineage, they are CD1a, CD2, CD3, CD4, CD5, CD7, and CD8 [95]. 
Cytogenetics and karyotyping are helpful in the identification of recurrent trans-
locations, chromosomal abnormalities, and numerical alterations. Fluorescence 
in situ hybridization (FISH) is a useful technique for detecting and localizing the 
presence or absence of specific DNA sequences on chromosomes, with 99% sen-
sitivity. Finally, array-comparative genomic hybridization (array-CGH, a-CGH) 
and single-nucleotide polymorphism (SNP) arrays can facilitate the identifica-
tion of cryptic and/or submicroscopic changes in the genome [96, 97]. Lumbar 
puncture with CSF analysis is the current standard of care for the diagnosis of 
CNS involvement. If the CNS is involved, brain MRIs should be performed. Other 
possible evaluations include a complete blood count alongside cytologic analysis 
of target cells to evaluate other hematopoietic cell lines, coagulation profiles, and 
serum chemistries [80].
3.4 Prognostic factors
ALL is a highly heterogeneous disease, and several clinical and biologic 
characteristics of ALL are used in risk stratification and prognostication. Disease 
characteristics (e.g., cytogenetics, molecular genetics, immunophenotypes) are 
substantially different between childhood, young adult, and adult ALL cases. 
Prognostic factors applied to ALL include age, white blood cell count (WBC), 
time to achieve a complete hematologic remission, minimal residual disease 
(MRD) persistence [98], and genetic aberrations. Older age and higher leukocyte 
count are associated with poor prognosis. Children older than 10 years with a 
leukocyte count exceeding 50,000/mm3 are classified as high risk according 
to the National Cancer Institute criteria (NCI-HR) [99]. ALL in young adults 
leads to poorer outcomes and exhibits high-risk genomic features (BCR-ABL1, 
BCR-ABL1-like, ETP-ALL [100], JAK mutation, CRLF2 alteration [101], iAMP21 
[102], or DUX4 translocation [103]). The National Cancer Institute defined 
adolescent and young adults (AYA) to be those aged 15–39 years old. AYAs may 
benefit from pediatric-inspired regimens and are thus considered separate 
from adults >40 years [104]. Elderly patients tend to have a form of the disease 
characterized by intrinsically unfavorable biology (BCR-ABL1, BCR-ABL1-like, 
hypodiploidy, and complex karyotype), more medical comorbidities, and an 
inability to tolerate standard chemotherapies. They also experience a higher risk 
of relapse. As such, patients over the age of 60 have particularly poor outcomes, 
with only 10–15% surviving long term [105]. Response to chemotherapy is a 
strong prognostic indicator in ALL. Clearance of leukemic blasts in the early 
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phase of treatment and the achievement of remission at the end of induction are 
predictors of relapse risk and have prognostic importance. Gender has also been 
recognized as a prognostic factor, with females having a better outcome than 
males overall.
3.4.1 Cytogenetic/genetic risk
Cytogenetic analyses have demonstrated that chromosomal aberrations 
(insertions, deletions, translocations, and inversions) and numerical alterations 
(hyperdiploid, pseudodiploid, and hypodiploid) are hallmarks of ALL [106]. The 
prevalence of genetic subtypes differs with age and is of prognostic relevance. 
Approximately half of pediatric leukemia cases involve aneuploidy (with changes 
in chromosome number), including high hyperdiploidy (50–67 chromosomes) or 
hypodiploidy (44 chromosomes or fewer) [107]. The chromosome most frequently 
gained in patients with high hyperdiploidy is 21 (>90% cases with trisomy or 
tetrasomy of chromosome 21) [108]. It is thought that the duplication of specific 
chromosomes contributes to leukemogenesis, making high hyperdiploidy a stronger 
prognostic factor than hypodiploidy. Hypodiploidy has been associated with dismal 
prognosis in all observed cases of ALL. Near-haploid (24–31 chromosomes) and 
low-hypodiploid (32–39 chromosomes) ALLs exhibit activation of Ras- and PI3K-
signaling pathways, suggesting that these pathways may be a target for therapy in 
aggressive hypodiploid ALLs [109]. Studies in the pediatric population have identi-
fied genetic syndromes that are connected to the predisposition in a minority of 
cases of ALL, such as Down syndrome, Fanconi anemia, Bloom syndrome, ataxia 
telangiectasia, and Nijmegen breakdown syndrome [89, 110, 111].
Characteristic translocations include erythroblast transformation-specific (ETS) 
variant 6–Runt-related transcription factor 1 (ETV6-RUNX1), the most common 
translocation (15–25% of pediatric ALL patients) caused by t(12;21)(p13;q22). 
The prognosis of ALL with ETV6-RUNX1 is excellent [112]. A second common 
translocation in pediatric ALL is transcription factor 3-PBX homeobox 1 (TCF3-
PBX1), which is caused by t(1;19)(q23;p13) and is observed in 5–10% of ALL cases. 
Previously, patients with this translocation were considered to have poor prognosis, 
but a recently improved treatment has resulted in better outcomes [113]. A small 
percentage of ALL patients (3–5%) exhibit the reciprocal translocation t(9;22)
(q34;q11), also referred to as the “Philadelphia (Ph) chromosome.” The Ph chromo-
some is largely prominent in patients suffering from chronic myeloid leukemia 
(CML) and is molecularly characterized by the creation of a non-receptor tyrosine 
kinase gene (BCR-ABL1) via the fusion of RhoGEF and GTPase-activating protein 
(BCR) and ABL proto-oncogene 1 (ABL1) [114].
The prevalence of t(9;22) in adult ALL can range from 15 to 50% and increases 
with age [115]. Ph chromosome positivity has been widely considered to be a factor 
for poor prognosis. The development of tyrosine kinase inhibitors (TKI), which 
directly target BCR-ABL1, has shown to significantly improve the treatment strat-
egy for Ph-ALL. Rearrangement of the mixed-lineage leukemia 1 gene (MML1), 
also known as KMT2A (lysine [K]-specific methyltransferase 2A), on chromo-
some 11q23 is found in a unique group of acute leukemias and predicts a very poor 
outcome [116].
More recently, a variant with a similar gene expression profile to Ph-positive 
ALL, but without the BCR-ABL1 rearrangement, has been identified. This so-called 
Ph-like ALL, or BCR-ABL1-like ALL, has been associated with poor response to 
induction chemotherapy, elevated minimal residual disease, and poor survival 
[117]. The prevalence of Ph-like ALL is common among all ages, ranging from 10 
to 15% in children to over 25% in young adults [118]. Patients with Ph-like ALL 
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harbor a diverse range of genetic alterations which activate cytokine receptor and 
kinase signaling pathways. Common genomic features of Ph-like ALL include 
alterations of B-lymphoid transcription factor genes (particularly IKZF1 deletions) 
as well as rearrangements and mutations of CRLF2, ABL-class tyrosine kinase 
genes, EPOR, JAK-STAT signaling, and RAS signaling (NRAS, KRAS, PTPN11, 
NF1) and other less common kinase alterations (FLT3, NTRK3, BLNK, TYK2, 
PTK2B) [119]. These mutated genes can be successfully targeted with tyrosine 
kinase inhibitors [117]. Another new high-risk subtype identified in diagnosis 
of ALL is B-ALL, which is characterized by intrachromosomal amplification of 
chromosome 21 (iAMP21) [102].
Genome-wide profiling studies have revealed components of multiple cellular 
and signaling pathways that are frequently mutated in ALL (referred to as coopera-
tive mutations). Deletions in key transcription factors involved in B-cell develop-
ment include IKAROS family zinc finger 1 (IKZF1), transcription factor 3 (E2A), 
early B-cell factor 1 (EBF1), and paired box 5 (PAX5). Kinase-activating mutations 
include rearrangements involving ABL1, JAK2, PDGFRB, CRLF2 and EPOR, 
activating mutations of IL7R and FLT3, and deletion of SH2B3, as well as mutations 
involved in tumor suppression (CDKN2A/CDKN2B, PTEN, and RB1), RAS signal-
ing (NRAS, KRAS, and PTPN11), transcriptional regulation (ETV6, ERG, TBL1XR1, 
and CREBBP), and epigenetic modification (CREBBP, EP300, SETD2, and NSD2) 
[117]. In all ALL subtypes, multiple cooperating mutations are acquired or enriched 
for during leukemia development and progression [120]. TP53 disruption has also 
been detected in relapsed B-ALL and T-ALL, as well as in newly diagnosed children 
and adult ALL cases. Correlation with poorer outcome has been illustrated and is 
associated with refractoriness to chemotherapy in adults [121].
Next-generation sequencing (NGS), most notably transcriptome sequencing, 
has led to the identification of several novel rearrangements that are not made evi-
dent by conventional genetic analysis, including DUX4-rearranged [122], MEF2D-
rearranged [103], and ZNF384-rearranged B-ALL and ETV6-RUNX1-like B-ALL 
[123]. These new ALL subtypes have distinct clinical and biological characteristics. 
The prognosis of the B-ALL subtypes is shown in Table 2.
Molecular subtype Prognosis Frequency (%) References
Hyperdiploid Favorable 20–30 [107, 108]
ETV6-RUNX1 Favorable 15–25 [112]
TCF3-PBX1 Intermediate 5–10 [113]
KMT2A rearranged Unfavorable 5 [116]
BCR-ABL1 Unfavorable 5–50 [114, 115]
BCR-ABL1 like Unfavorable 10–25 [118]
Hypodiploid Unfavorable 3 [109]
iAMP21 unfavorable 2 [102]
DUX4 rearranged Favorable 4–5 [122]
MEF2D rearranged Unfavorable 2–3 [103]
ZNF384 rearranged Intermediate 2–3 [123]
ETV6-RUNX1 like Intermediate 2–3 [123]
Favorable, intermediate, and unfavorable prognoses of acute lymphoblastic leukemia (ALL) subtypes are associated 
with 5-year overall survival of >90%, 70–90%, and <70%, respectively.
Table 2. 
Prognosis in B-ALL.
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T-ALL is characterized by numerous transcriptional, signaling, and epigen-
etic factors. Activating mutations in NOTCH1 can be found in the majority of 
T-ALL cases and predict a favorable prognosis [124]. Deletions of the CDKN2A 
locus encoding the P16/INK4A and P19/ARF tumor suppressors, responsible for 
control of cell cycle progression and P53 regulation, respectively, are present 
in about 70% of T-ALLs [125]. Gene expression profiling has identified major 
categories of T-ALL associated with gene expression during thymocyte develop-
ment. Cytokine receptor RAS signaling genes, which include FLT3, have been 
found to be activated by mutation in early T-cell precursor T-ALL (ETP T-ALL). 
In addition, alterations in genes which disturb hematopoietic development, such 
as GATA 3, ETV6, and RUNX1, have been observed. Lastly, mutations in histone-
modifying genes (EZH2, SUZ12, and EED) are also a consequence of ETP 
T-ALL. ETP T-ALL has been associated with poor prognosis [126]. Early cortical 
thymocyte leukemias are primarily associated with translocations resulting in 
aberrant expression of TLX1, TLX3, and related homeobox transcription factor 
oncogenes; these exhibit a characteristically favorable outcome [125, 127]. Late 
cortical leukemias occur further down in the pattern of gene expression pro-
gramming related to T-cell development, overexpressing the transcription factor 
oncogene TAL1 with either LMO1 or LMO2 and PTEN. These are associated with 
poor prognosis [125, 127].
3.5 Therapy
Typical chemotherapy consists of induction, consolidation, and long-term 
maintenance, with CNS prophylaxis given at intervals throughout therapy. The 
goal of induction therapy is to achieve complete remission and to restore a normal 
blood cell count. Predominantly 85–90% of patients achieve complete remission 
after 4–6 weeks of this regimen [128]. Several chemotherapeutic agents are cur-
rently used in the treatment of CLL, including amascrine, asparaginase, cyclo-
phosphamide, cytarabine, daunorubicin, dexamethasone, and methotrexate. Each 
utilizes slightly differing mechanisms of action; in the general sense however, these 
molecules affect the growth and division of cancer cells by inducing DNA damage 
[129]. Multi-agent cytotoxic chemotherapy has had great success in pediatric age 
groups [130]. Pediatric-inspired treatment protocols have also shown superior 
outcomes in young adults [104], but the same success has not been reproduced in 
adults despite regime modifications. Traditional adult treatment protocols include 
intensive myelosuppressive agents as well as allogeneic hematopoietic stem cell 
transplant (allo-SCT) in first remission [104]. After achieving complete response, 
treatment options include consolidation and maintenance chemotherapy or allo-
SCT for eligible patients [131]. For high-risk patients (Ph-positive ALL, elevated 
WBC count, CNS disease, high-risk gene rearrangements, or hypodiploidy) and 
patients with relapsed/refractory disease, allo-SCT has long been considered 
the standard of care. However, the advent of TKIs marked a turning point in the 
treatment of some high-risk subtypes such as Ph-ALL and Ph-like ALL. After 
induction therapy, subsequent consolidation therapy begins to eradicate residual 
leukemic cells. Consolidation varies in different protocols but generally utilizes 
similar agents for induction (various combinations of cytotoxic agents and high 
dose of escalating methotrexate) and at times includes intrathecal chemotherapy 
and cranial radiation for CNS prophylaxis [132]. Maintenance therapy typically 
lasts 1–2 years. Daily 6-mercaptopurine (6-MP) and weekly MTX are a standard 
combination, and some maintenance therapies are enhanced with vincristine and 
steroids [80].
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A better understanding of the molecular landscape of ALL and advances in the 
field of monoclonal antibody therapy have resulted in the development of several 
new agents, especially in the treatment of adolescent and young adults (AYA) and 
adult patients. Targeted delivery of monoclonal antibodies based on leukemic cell-
surface receptor recognition improves efficacy and minimizes off-target toxicity. 
The antigens CD19, CD20, CD22, and CD52 are the most common antigens to 
which monoclonal antibodies in B-cell ALL have been directed. Rituximab is 
a non-conjugated monoclonal antibody designed to target a single antigen on 
the tumor cell surface. The combination of rituximab with chemotherapy in 
the frontline treatment of CD20-positive B-ALL has been shown to increase 
CR duration, lower relapse rates, and improve event-free survival [133]. A new 
generation of monoclonal antibodies exists which is characterized by the antibody 
being conjugated to drug or toxins with the purpose of enhancing the efficiency 
of cancer cell killing. For example, inotuzumab ozogamicin (IO) is a monoclonal 
antibody against CD22 linked to the cytotoxic agent, calicheamicin. The use of 
IO alone, and in combination with chemotherapy, has shown promise in relapsed 
and refractory B-cell ALL [134]. Other modifications to antibody constructs can 
also augment immunogenic reactions against leukemia. Blinatumomab is the first 
approved drug in the BiTE class, a bispecific T-cell receptor engager, which has 
both a monoclonal antibody against CD19 and an anti-CD3 T cell-binding domain. 
Monotherapy in relapsed and refractory B-cell ALL has resulted in prolonged 
relapse-free survival [135]. The effectiveness and safety of several newer mono-
clonal antibodies including ofatumumab [136], obinutuzumab, epratuzumab 
[137], and moxetumomab pasudotox [138] as single agents or in combination with 
a chemotherapeutic are currently under investigation. Chimeric antigen recep-
tor (CAR) therapy has shown remarkable efficacy in B-cell ALL. CAR combines 
both antigen-binding and T-cell activating functions into a single receptor. 
CAR-modified T cells involve a mechanism in which a patient’s own T cells are 
genetically programmed to recognize leukemic cells, inducing an antileukemic 
immune response. Complete remission rates as high as 90% have been reported in 
children and adults with relapsed and refractory ALL posttreatment with CAR-
modified T cells targeting the B cell-specific antigen CD19 [139]. Treatment of 
the high-risk Ph-like ALL has significantly improved with the identification of 
genetic alterations which deregulate cytokine receptor and tyrosine kinase signal-
ing, both common features of this subtype of ALL. Tyrosine kinase inhibitors 
(TKIs) such as imatinib, dasatinib, nilotinib, and ponatinib, NOTCH1 and DOT1L 
pathway inhibitors, and JAK inhibitors have become novel agents for Ph-like ALL 
therapy. In addition, 50% of Ph-like ALLs show activation of phosphatidylinosi-
tol 3-kinase/protein kinase B (PI3K/AKT) and mammalian target of rapamycin 
(mTOR) pathways and could therefore present potential targets for mTOR 
inhibitors [140]. Inhibition of the PI3K/AKT/mTOR pathways may be an effective 
treatment for T-ALL.
4. Protein markers of CLL and ALL as a new therapeutic targets
New specific protein markers connected with CLL and ALL which have been 
discovered in the last 10–15 years represent novel potential targets for highly 
personalized treatments of leukemia. These proteins, associated with differ-
ent cellular signaling events, mostly include surface receptors/transmembrane 
proteins—CD5, CD19, CD20, CD22, CD23, CD52, and many others [9, 11, 31, 
33, 38]—where protein phosphorylation may play an important role in protein 
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activity regulation connected to the progression of disease and regulation of 
pathological events [12–14]. Focusing on such specific modifications presents 
key opportunities to further facilitate efficient and precise drug strategy design 
[55–58]. Inhibition of protein kinases associated with key phosphorylations has 
been an intense research topic in the last decade [67–69, 72, 73, 75]. Significant 
progress in protein mass spectrometry techniques, specific antibody design and 
development, parallel studies of genes, epigenetic proteome, and related proteins 
including their disease-related modifications altogether open a new horizon for a 
more sensitive and personalized approach to the diagnosis and treatment methods 
of CLL and ALL. The combination of such approaches should further facilitate 
the development of more efficient drugs and approaches which more specifi-
cally target the key signaling events concerning the onset and progression of the 
disease. Based on the fact that proteome maps are unique to each individual, there 
is an urgent need for personalized diagnostics and a personalized molecular treat-
ment approach. Using the information from the proteins associated with the CLL 
and ALL, and the misregulation of signaling pathways in associated cell regulation 
events, the precise and detailed protein signaling outcome can form the base of 
potential success in the domain of efficient drug design and consequent molecular 
treatment, without the typical side effects of current conventional methods.
5. Conclusion
Given the diverse molecular and genetic alterations occurring in both CLL and 
ALL, it is unlikely that a single and unique therapeutic approach will be effective 
across all patients. Great progress has been made thus far in the identification of 
oncogenic drivers and therapeutic targets. However, although treatment regimens 
have advanced significantly, they continue to present many challenges for the 
majority of patients, including toxicity. Future studies focused on the identification 
of biomarkers should result in more effective treatments exhibiting antileuke-
mic activity with reduced toxicity. Furthermore, highly targeted therapy can be 
expected to lead to improvements in remission and survival as part of individual-
ized treatment strategies.
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